Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | TTPA | P49638 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12753940 | 1.00 | LMNA (0.42) | LMNABLMPTPN1TTPA | |
| SCHEMBL12753939 | 1.00 | LMNA (0.42) | LMNABLMPTPN1TTPA | |
| SCHEMBL12753905 | 0.96 | LMNA (0.42) | LMNABLM | |
| SCHEMBL12374846 | 0.96 | LMNA (0.42) | LMNABLM | |
| SCHEMBL12753907 | 0.96 | LMNA (0.42) | LMNABLM | |
| SCHEMBL12753910 | 0.86 | CA1 (0.31) | — | |
| SCHEMBL12753883 | 0.86 | CA1 (0.31) | — | |
| SCHEMBL12753913 | 0.86 | CA1 (0.31) | — | |
| SCHEMBL14476657 | 0.84 | PTGS1 (0.33) | — | |
| SCHEMBL6014859 | 0.83 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | LMNA 4141/4885BLM 4207/4885PTPN1 2171/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | LMNA 2520/4885BLM 3594/4885PTPN1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.